We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Follow-up Protocol for Patients With Cancer/AIDS/Skin Disease

This study is enrolling participants by invitation only.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00001503
First Posted: November 4, 1999
Last Update Posted: November 8, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
National Institutes of Health Clinical Center (CC) ( National Cancer Institute (NCI) )
November 3, 1999
November 4, 1999
November 8, 2017
May 2, 1996
Not Provided
To provide follow-up for patients who are long term survivors previously enrolled Center for Cancer Research (CCR) trial but who may not currently be enrolled on a research protocol [ Time Frame: 30 years ]
Not Provided
Complete list of historical versions of study NCT00001503 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Follow-up Protocol for Patients With Cancer/AIDS/Skin Disease
Follow-up for Patients Previously Enrolled on the Center for Cancer Research Protocols
This protocol is to provide follow-up medical/surgical visits for DCS patients who are long term survivors and may not currently be a participant entered on an active research protocol. No investigational treatments or standard treatments will be administered on this protocol.

Background:

  • Patients enrolled on CCR clinical protocols may require long term follow-up to assess outcome (e.g., survival) or the effects of prior therapy.
  • Keeping the primary treatment protocols open after accrual is complete in order to follow patients for long term outcome is an administrative burden on investigators and the IRB.

Objectives:

-To provide follow-up for patients who are long term survivors previously enrolled Center for Cancer Research (CCR) trial but who may not currently be enrolled on a research protocol.

Eligibility:

-Patients who were previously enrolled on a CCR protocol and who are not eligible for an active NCI intramural primary research protocol.

Design:

  • The medical procedures/tests will be based on the patient's diagnosis, treatment and supporting clinical information. This is a follow-up study in which only standard tests and procedures are to be performed.
  • Clinical information that is relevant to the patients prior protocols will be collected for research purposes.
  • Procedures that entail more than minimal risk to the patient should not be performed for research purposes on this protocol.
Observational
Observational Model: Cohort
Time Perspective: Prospective
Not Provided
Not Provided
Not Provided
Not Provided
  • Melanoma
  • Ovarian Cancer
  • Prostate Cancer
  • Breast Cancer
  • Lymphoma
Not Provided
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Enrolling by invitation
990
Not Provided
Not Provided
  • ELIGIBILITY CRITERIA:

Patients of any age who were previously enrolled on a CCR protocol.

Not eligible for or unwilling to participate in an active NCI intramural primary research protocol.

CCR investigator decides it is in the best interests of the patient and the CC for the patient to be seen in follow-up visits at the NIH.

Patient or Legally Authorized Representative (LAR)/guardian is able to provide informed consent.

Sexes Eligible for Study: All
up to 100 Years   (Child, Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
United States
 
 
NCT00001503
960071
96-C-0071
Not Provided
Not Provided
Not Provided
National Institutes of Health Clinical Center (CC) ( National Cancer Institute (NCI) )
National Cancer Institute (NCI)
Not Provided
Principal Investigator: Caryn Steakley, R.N. National Cancer Institute (NCI)
National Institutes of Health Clinical Center (CC)
October 27, 2017